Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

IntraBio Inc. today announced positive topline results from its pivotal Phase III IB1001-303 clinical trial, "Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Randomized, ...

If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

Barbara Sharp Barbara Sharp, 66, passed away peacefully at her home in Santa Barbara on Tuesday, Jan. 13, 2026, after living ...

As IntraBio works to grow the global treatment market for Aqneursa in Niemann-Pick disease type C, the company is already ...

A woman who is alleged to have failed in providing vet care, food and shelter to 27 horses, including ponies and a pregnant ...

Welcome back to a new semester of Dissertation Diaries. As a reminder, this is the series where we highlight Ph.D. students ...

Scientists at Johns Hopkins have uncovered a surprising new way to influence brain activity by targeting a long-mysterious class of proteins linked to anxiety, schizophrenia, and movement disorders.

IntraBio Inc. today announced that the European Commission granted marketing authorization to AQNEURSA® (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) ...

The DWP has issued a full list of 533 conditions which could qualify you for a £187 a week payment. Personal Independence ...

Johns Hopkins researchers found that delta-type ionotropic glutamate receptors (GluDs) play a key role in regulating neuronal ...

Scientists reveal the GluD brain protein's active role, offering new hope for mental health. Discover how this breakthrough ...